Registry for rare ovarian and testicular stromal tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry collects and analyzes clinical and biological data on ovarian and testicular stromal tumors to better understand their causes and treatment options. It gathers information through referrals from clinicians, families, and published case authors, focusing on factors such as clinical history, family history, imaging studies, and treatment outcomes. The registry also collects biological samples for genetic analysis, particularly looking at DICER1 mutations and miRNA expression, which may play a role in these tumors. The goal is to improve knowledge and treatment strategies for these rare cancers.

Why it matters

Who can join: the full rules

All patients with a suspected gonadal stromal tumor or a similar tumor. International enrollment is encouraged. Patients of any age are eligible, but based on epidemiology and referral patterns, most participants are expected to be under age 20.

Where it's running

• Children's Minnesota
  Minneapolis, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Kris Ann P Schultz, MD — Children's Minnesota
• Study coordinator: Paige HR Mallinger, MS
• Email: paige.mallinger@childrensmn.org
• Phone: 612-813-7121

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing two chemotherapy regimens for ovarian malignant sex cord-stromal tumors

  This study is testing if a new combination of chemotherapy drugs can help people with newly diagnosed ovarian malignant sex cord-stromal tumors live longer and feel better compared to the standard treatment.

  Recruiting Phase 3 Shandong University · Jinan, Shandong · NCT02429700

• Combining Pembrolizumab with standard chemotherapy for small cell ovarian carcinoma

  This study is testing if adding the immunotherapy drug Pembrolizumab to standard chemotherapy can help people aged 12 and older with small cell ovarian carcinoma feel better and live longer.

  Recruiting at 6 sites Phase 2 Arcagy/ Gineco Group · Angers and 12 other locations · NCT04602377

• Comparing in-person and remote monitoring for cancer follow-up

  This study is testing whether patients with rare tumors follow their post-treatment care plans better with in-person visits from a doctor or remote check-ins with a nurse.

  Recruiting Phase 2 Centre Oscar Lambret · Amiens and 2 other locations · NCT05500391

• Sacituzumab tirumotecan with or without pembrolizumab in ovarian clear cell cancer that has come back or spread

  This phase II study tests Sacituzumab tirumotecan alone or with pembrolizumab in adults whose ovarian clear cell cancer has recurred or spread after prior PD-1 therapy.

  Recruiting Phase 2 Tufts Medical Center · Boston, Massachusetts · NCT07718854

• QL1706 and Bevacizumab as first-line treatment for advanced ovarian clear cell carcinoma

  This trial tests whether combining QL1706 with bevacizumab can give adults with newly diagnosed advanced ovarian clear cell carcinoma better outcomes than the standard platinum-based chemotherapy.

  Recruiting Phase 3 Tongji Hospital · Wuhan, Hubei · NCT07002346

• Combining dostarlimab and LB-100 for treating ovarian clear cell carcinoma

  This study is testing whether combining two treatments, dostarlimab and LB-100, can help people with recurrent ovarian clear cell carcinoma live longer and feel better.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT06065462

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.